{"id":"NCT06354998","sponsor":"ModernaTX, Inc.","briefTitle":"A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults","officialTitle":"Randomized, Observer-Blind, Active-Controlled, Clinical Trial to Assess the Immunogenicity of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2024-04-08","primaryCompletion":"2024-05-10","completion":"2024-05-10","firstPosted":"2024-04-09","resultsPosted":"2025-05-25","lastUpdate":"2025-05-25"},"enrollment":217,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["SARS-CoV-2"],"interventions":[{"type":"BIOLOGICAL","name":"Investigational mRNA-1273.815","otherNames":[]},{"type":"BIOLOGICAL","name":"Licensed Spikevax Vaccine","otherNames":[]}],"arms":[{"label":"Investigational mRNA-1273.815","type":"EXPERIMENTAL"},{"label":"Licensed Spikevax Vaccine","type":"ACTIVE_COMPARATOR"}],"summary":"To evaluate immune responses of an Investigational mRNA-1273.815 vaccine against the Omicron subvariant strain (XBB.1.5) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).","primaryOutcome":{"measure":"Geometric Mean (GM) Value of Neutralizing Antibodies (nAbs) Against SARS-CoV-2-specific Strain at Day 15","timeFrame":"Day 15","effectByArm":[{"arm":"Investigational mRNA-1273.815","deltaMin":1180.55,"sd":null},{"arm":"Licensed Spikevax Vaccine","deltaMin":1300.25,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":8},"locations":{"siteCount":7,"countries":["Australia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":106},"commonTop":[]}}